New RNA & DNA-sequencing platform matches thousands of drugs to late-stage cancer patients

(The Mount Sinai Hospital / Mount Sinai School of Medicine) A comprehensive RNA and DNA sequencing platform benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them, according to results from a clinical trial published in JCO Precision Oncology in August.